Global Homozygous Familial Hypercholesterolemia Treatment Market Insights and Forecast to 2031

Report ID: 1563942 | Published Date: Jan 2025 | No. of Page: 89 | Base Year: 2024 | Rating: 4 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Study Coverage
    1.1 Homozygous Familial Hypercholesterolemia Treatment Product Introduction
    1.2 Market by Type
        1.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 AEM-2802
        1.2.3 AEM-2814
        1.2.4 Alirocumab
        1.2.5 Evinacumab
        1.2.6 Others
    1.3 Market by Application
        1.3.1 Global Homozygous Familial Hypercholesterolemia Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Clinic
        1.3.3 Hospital
        1.3.4 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales Estimates and Forecasts 2017-2028
    2.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Estimates and Forecasts 2017-2028
    2.3 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region
        2.4.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2017-2022)
        2.4.2 Global Sales Homozygous Familial Hypercholesterolemia Treatment by Region (2023-2028)
    2.5 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region
        2.5.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2017-2022)
        2.5.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Manufacturers
        3.1.1 Global Top Homozygous Familial Hypercholesterolemia Treatment Manufacturers by Sales (2017-2022)
        3.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Homozygous Familial Hypercholesterolemia Treatment in 2021
    3.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Manufacturers
        3.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Manufacturers (2017-2022)
        3.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Homozygous Familial Hypercholesterolemia Treatment Revenue in 2021
    3.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Homozygous Familial Hypercholesterolemia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Homozygous Familial Hypercholesterolemia Treatment Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type
        4.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Historical Sales by Type (2017-2022)
        4.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Forecasted Sales by Type (2023-2028)
        4.1.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2017-2028)
    4.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type
        4.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Historical Revenue by Type (2017-2022)
        4.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2017-2028)
    4.3 Global Homozygous Familial Hypercholesterolemia Treatment Price by Type
        4.3.1 Global Homozygous Familial Hypercholesterolemia Treatment Price by Type (2017-2022)
        4.3.2 Global Homozygous Familial Hypercholesterolemia Treatment Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application
        5.1.1 Global Homozygous Familial Hypercholesterolemia Treatment Historical Sales by Application (2017-2022)
        5.1.2 Global Homozygous Familial Hypercholesterolemia Treatment Forecasted Sales by Application (2023-2028)
        5.1.3 Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2017-2028)
    5.2 Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application
        5.2.1 Global Homozygous Familial Hypercholesterolemia Treatment Historical Revenue by Application (2017-2022)
        5.2.2 Global Homozygous Familial Hypercholesterolemia Treatment Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2017-2028)
    5.3 Global Homozygous Familial Hypercholesterolemia Treatment Price by Application
        5.3.1 Global Homozygous Familial Hypercholesterolemia Treatment Price by Application (2017-2022)
        5.3.2 Global Homozygous Familial Hypercholesterolemia Treatment Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Homozygous Familial Hypercholesterolemia Treatment Market Size by Type
        6.1.1 North America Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2028)
        6.1.2 North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2017-2028)
    6.2 North America Homozygous Familial Hypercholesterolemia Treatment Market Size by Application
        6.2.1 North America Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2028)
        6.2.2 North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2017-2028)
    6.3 North America Homozygous Familial Hypercholesterolemia Treatment Market Size by Country
        6.3.1 North America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2028)
        6.3.2 North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Homozygous Familial Hypercholesterolemia Treatment Market Size by Type
        7.1.1 Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2028)
        7.1.2 Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2017-2028)
    7.2 Europe Homozygous Familial Hypercholesterolemia Treatment Market Size by Application
        7.2.1 Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2028)
        7.2.2 Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2017-2028)
    7.3 Europe Homozygous Familial Hypercholesterolemia Treatment Market Size by Country
        7.3.1 Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2028)
        7.3.2 Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Market Size by Type
        8.1.1 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2028)
        8.1.2 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2017-2028)
    8.2 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Market Size by Application
        8.2.1 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2028)
        8.2.2 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2017-2028)
    8.3 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Market Size by Region
        8.3.1 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2017-2028)
        8.3.2 Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Homozygous Familial Hypercholesterolemia Treatment Market Size by Type
        9.1.1 Latin America Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2028)
        9.1.2 Latin America Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2017-2028)
    9.2 Latin America Homozygous Familial Hypercholesterolemia Treatment Market Size by Application
        9.2.1 Latin America Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2028)
        9.2.2 Latin America Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2017-2028)
    9.3 Latin America Homozygous Familial Hypercholesterolemia Treatment Market Size by Country
        9.3.1 Latin America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2028)
        9.3.2 Latin America Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Market Size by Type
        10.1.1 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2017-2028)
    10.2 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Market Size by Application
        10.2.1 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2017-2028)
    10.3 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Market Size by Country
        10.3.1 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 CymaBay Therapeutics Inc
        11.1.1 CymaBay Therapeutics Inc Corporation Information
        11.1.2 CymaBay Therapeutics Inc Overview
        11.1.3 CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 CymaBay Therapeutics Inc Recent Developments
    11.2 Daewoong Co Ltd
        11.2.1 Daewoong Co Ltd Corporation Information
        11.2.2 Daewoong Co Ltd Overview
        11.2.3 Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 Daewoong Co Ltd Recent Developments
    11.3 Gemphire Therapeutics Inc
        11.3.1 Gemphire Therapeutics Inc Corporation Information
        11.3.2 Gemphire Therapeutics Inc Overview
        11.3.3 Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Gemphire Therapeutics Inc Recent Developments
    11.4 LipimetiX Development Inc
        11.4.1 LipimetiX Development Inc Corporation Information
        11.4.2 LipimetiX Development Inc Overview
        11.4.3 LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 LipimetiX Development Inc Recent Developments
    11.5 Regeneron Pharmaceuticals Inc
        11.5.1 Regeneron Pharmaceuticals Inc Corporation Information
        11.5.2 Regeneron Pharmaceuticals Inc Overview
        11.5.3 Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 Regeneron Pharmaceuticals Inc Recent Developments
    11.6 RegenxBio Inc
        11.6.1 RegenxBio Inc Corporation Information
        11.6.2 RegenxBio Inc Overview
        11.6.3 RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 RegenxBio Inc Recent Developments
    11.7 The Medicines Company
        11.7.1 The Medicines Company Corporation Information
        11.7.2 The Medicines Company Overview
        11.7.3 The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 The Medicines Company Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Homozygous Familial Hypercholesterolemia Treatment Industry Chain Analysis
    12.2 Homozygous Familial Hypercholesterolemia Treatment Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Homozygous Familial Hypercholesterolemia Treatment Production Mode & Process
    12.4 Homozygous Familial Hypercholesterolemia Treatment Sales and Marketing
        12.4.1 Homozygous Familial Hypercholesterolemia Treatment Sales Channels
        12.4.2 Homozygous Familial Hypercholesterolemia Treatment Distributors
    12.5 Homozygous Familial Hypercholesterolemia Treatment Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Homozygous Familial Hypercholesterolemia Treatment Industry Trends
    13.2 Homozygous Familial Hypercholesterolemia Treatment Market Drivers
    13.3 Homozygous Familial Hypercholesterolemia Treatment Market Challenges
    13.4 Homozygous Familial Hypercholesterolemia Treatment Market Restraints
14 Key Findings in The Global Homozygous Familial Hypercholesterolemia Treatment Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer

List of Tables
    Table 1. Global Homozygous Familial Hypercholesterolemia Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of AEM-2802
    Table 3. Major Manufacturers of AEM-2814
    Table 4. Major Manufacturers of Alirocumab
    Table 5. Major Manufacturers of Evinacumab
    Table 6. Major Manufacturers of Others
    Table 7. Global Homozygous Familial Hypercholesterolemia Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 8. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 9. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2017-2022) & (K Pcs)
    Table 10. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region (2017-2022)
    Table 11. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2023-2028) & (K Pcs)
    Table 12. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region (2023-2028)
    Table 13. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2017-2022) & (US$ Million)
    Table 14. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Region (2017-2022)
    Table 15. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2023-2028) & (US$ Million)
    Table 16. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Region (2023-2028)
    Table 17. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Manufacturers (2017-2022) & (K Pcs)
    Table 18. Global Homozygous Familial Hypercholesterolemia Treatment Sales Share by Manufacturers (2017-2022)
    Table 19. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 20. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Manufacturers (2017-2022)
    Table 21. Homozygous Familial Hypercholesterolemia Treatment Price by Manufacturers (2017-2022) &(USD/Pcs)
    Table 22. Global Homozygous Familial Hypercholesterolemia Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 23. Global Homozygous Familial Hypercholesterolemia Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Homozygous Familial Hypercholesterolemia Treatment as of 2021)
    Table 24. Homozygous Familial Hypercholesterolemia Treatment Manufacturing Base Distribution and Headquarters
    Table 25. Manufacturers Homozygous Familial Hypercholesterolemia Treatment Product Offered
    Table 26. Date of Manufacturers Enter into Homozygous Familial Hypercholesterolemia Treatment Market
    Table 27. Mergers & Acquisitions, Expansion Plans
    Table 28. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2022) & (K Pcs)
    Table 29. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2023-2028) & (K Pcs)
    Table 30. Global Homozygous Familial Hypercholesterolemia Treatment Sales Share by Type (2017-2022)
    Table 31. Global Homozygous Familial Hypercholesterolemia Treatment Sales Share by Type (2023-2028)
    Table 32. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2017-2022) & (US$ Million)
    Table 33. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2023-2028) & (US$ Million)
    Table 34. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Type (2017-2022)
    Table 35. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Type (2023-2028)
    Table 36. Homozygous Familial Hypercholesterolemia Treatment Price by Type (2017-2022) & (USD/Pcs)
    Table 37. Global Homozygous Familial Hypercholesterolemia Treatment Price Forecast by Type (2023-2028) & (USD/Pcs)
    Table 38. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2022) & (K Pcs)
    Table 39. Global Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2023-2028) & (K Pcs)
    Table 40. Global Homozygous Familial Hypercholesterolemia Treatment Sales Share by Application (2017-2022)
    Table 41. Global Homozygous Familial Hypercholesterolemia Treatment Sales Share by Application (2023-2028)
    Table 42. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2017-2022) & (US$ Million)
    Table 43. Global Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2023-2028) & (US$ Million)
    Table 44. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Application (2017-2022)
    Table 45. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Application (2023-2028)
    Table 46. Homozygous Familial Hypercholesterolemia Treatment Price by Application (2017-2022) & (USD/Pcs)
    Table 47. Global Homozygous Familial Hypercholesterolemia Treatment Price Forecast by Application (2023-2028) & (USD/Pcs)
    Table 48. North America Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2022) & (K Pcs)
    Table 49. North America Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2023-2028) & (K Pcs)
    Table 50. North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2017-2022) & (US$ Million)
    Table 51. North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2023-2028) & (US$ Million)
    Table 52. North America Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2022) & (K Pcs)
    Table 53. North America Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2023-2028) & (K Pcs)
    Table 54. North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2017-2022) & (US$ Million)
    Table 55. North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2023-2028) & (US$ Million)
    Table 56. North America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2022) & (K Pcs)
    Table 57. North America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2023-2028) & (K Pcs)
    Table 58. North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2022) & (US$ Million)
    Table 59. North America Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2023-2028) & (US$ Million)
    Table 60. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2022) & (K Pcs)
    Table 61. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2023-2028) & (K Pcs)
    Table 62. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2017-2022) & (US$ Million)
    Table 63. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2023-2028) & (US$ Million)
    Table 64. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2022) & (K Pcs)
    Table 65. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2023-2028) & (K Pcs)
    Table 66. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2017-2022) & (US$ Million)
    Table 67. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2023-2028) & (US$ Million)
    Table 68. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2022) & (K Pcs)
    Table 69. Europe Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2023-2028) & (K Pcs)
    Table 70. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2022) & (US$ Million)
    Table 71. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2023-2028) & (US$ Million)
    Table 72. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2022) & (K Pcs)
    Table 73. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2023-2028) & (K Pcs)
    Table 74. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2017-2022) & (US$ Million)
    Table 75. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2023-2028) & (US$ Million)
    Table 76. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2022) & (K Pcs)
    Table 77. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2023-2028) & (K Pcs)
    Table 78. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2017-2022) & (US$ Million)
    Table 79. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2023-2028) & (US$ Million)
    Table 80. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2017-2022) & (K Pcs)
    Table 81. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales by Region (2023-2028) & (K Pcs)
    Table 82. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2017-2022) & (US$ Million)
    Table 83. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue by Region (2023-2028) & (US$ Million)
    Table 84. Latin America Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2022) & (K Pcs)
    Table 85. Latin America Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2023-2028) & (K Pcs)
    Table 86. Latin America Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2017-2022) & (US$ Million)
    Table 87. Latin America Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2023-2028) & (US$ Million)
    Table 88. Latin America Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2022) & (K Pcs)
    Table 89. Latin America Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2023-2028) & (K Pcs)
    Table 90. Latin America Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2017-2022) & (US$ Million)
    Table 91. Latin America Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2023-2028) & (US$ Million)
    Table 92. Latin America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2022) & (K Pcs)
    Table 93. Latin America Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2023-2028) & (K Pcs)
    Table 94. Latin America Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2022) & (US$ Million)
    Table 95. Latin America Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2023-2028) & (US$ Million)
    Table 96. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2017-2022) & (K Pcs)
    Table 97. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Type (2023-2028) & (K Pcs)
    Table 98. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2017-2022) & (US$ Million)
    Table 99. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Type (2023-2028) & (US$ Million)
    Table 100. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2017-2022) & (K Pcs)
    Table 101. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Application (2023-2028) & (K Pcs)
    Table 102. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2017-2022) & (US$ Million)
    Table 103. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Application (2023-2028) & (US$ Million)
    Table 104. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2017-2022) & (K Pcs)
    Table 105. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales by Country (2023-2028) & (K Pcs)
    Table 106. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2017-2022) & (US$ Million)
    Table 107. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue by Country (2023-2028) & (US$ Million)
    Table 108. CymaBay Therapeutics Inc Corporation Information
    Table 109. CymaBay Therapeutics Inc Description and Major Businesses
    Table 110. CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 111. CymaBay Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Model Numbers, Pictures, Descriptions and Specifications
    Table 112. CymaBay Therapeutics Inc Recent Developments
    Table 113. Daewoong Co Ltd Corporation Information
    Table 114. Daewoong Co Ltd Description and Major Businesses
    Table 115. Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 116. Daewoong Co Ltd Homozygous Familial Hypercholesterolemia Treatment Product Model Numbers, Pictures, Descriptions and Specifications
    Table 117. Daewoong Co Ltd Recent Developments
    Table 118. Gemphire Therapeutics Inc Corporation Information
    Table 119. Gemphire Therapeutics Inc Description and Major Businesses
    Table 120. Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 121. Gemphire Therapeutics Inc Homozygous Familial Hypercholesterolemia Treatment Product Model Numbers, Pictures, Descriptions and Specifications
    Table 122. Gemphire Therapeutics Inc Recent Developments
    Table 123. LipimetiX Development Inc Corporation Information
    Table 124. LipimetiX Development Inc Description and Major Businesses
    Table 125. LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 126. LipimetiX Development Inc Homozygous Familial Hypercholesterolemia Treatment Product Model Numbers, Pictures, Descriptions and Specifications
    Table 127. LipimetiX Development Inc Recent Developments
    Table 128. Regeneron Pharmaceuticals Inc Corporation Information
    Table 129. Regeneron Pharmaceuticals Inc Description and Major Businesses
    Table 130. Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 131. Regeneron Pharmaceuticals Inc Homozygous Familial Hypercholesterolemia Treatment Product Model Numbers, Pictures, Descriptions and Specifications
    Table 132. Regeneron Pharmaceuticals Inc Recent Developments
    Table 133. RegenxBio Inc Corporation Information
    Table 134. RegenxBio Inc Description and Major Businesses
    Table 135. RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 136. RegenxBio Inc Homozygous Familial Hypercholesterolemia Treatment Product Model Numbers, Pictures, Descriptions and Specifications
    Table 137. RegenxBio Inc Recent Developments
    Table 138. The Medicines Company Corporation Information
    Table 139. The Medicines Company Description and Major Businesses
    Table 140. The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 141. The Medicines Company Homozygous Familial Hypercholesterolemia Treatment Product Model Numbers, Pictures, Descriptions and Specifications
    Table 142. The Medicines Company Recent Developments
    Table 143. Key Raw Materials Lists
    Table 144. Raw Materials Key Suppliers Lists
    Table 145. Homozygous Familial Hypercholesterolemia Treatment Distributors List
    Table 146. Homozygous Familial Hypercholesterolemia Treatment Customers List
    Table 147. Homozygous Familial Hypercholesterolemia Treatment Market Trends
    Table 148. Homozygous Familial Hypercholesterolemia Treatment Market Drivers
    Table 149. Homozygous Familial Hypercholesterolemia Treatment Market Challenges
    Table 150. Homozygous Familial Hypercholesterolemia Treatment Market Restraints
    Table 151. Research Programs/Design for This Report
    Table 152. Key Data Information from Secondary Sources
    Table 153. Key Data Information from Primary Sources
List of Figures
    Figure 1. Homozygous Familial Hypercholesterolemia Treatment Product Picture
    Figure 3. Global Homozygous Familial Hypercholesterolemia Treatment Market Share by Type in 2021 & 2028
    Figure 3. AEM-2802 Product Picture
    Figure 4. AEM-2814 Product Picture
    Figure 5. Alirocumab Product Picture
    Figure 6. Evinacumab Product Picture
    Figure 7. Others Product Picture
    Figure 8. Global Homozygous Familial Hypercholesterolemia Treatment Market Share by Application in 2021 & 2028
    Figure 9. Clinic
    Figure 10. Hospital
    Figure 11. Others
    Figure 12. Homozygous Familial Hypercholesterolemia Treatment Report Years Considered
    Figure 13. Global Homozygous Familial Hypercholesterolemia Treatment Sales 2017-2028 (K Pcs)
    Figure 14. Global Homozygous Familial Hypercholesterolemia Treatment Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 15. Global Homozygous Familial Hypercholesterolemia Treatment Revenue 2017-2028 (US$ Million)
    Figure 16. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 17. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region (2017-2022)
    Figure 18. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Region (2023-2028)
    Figure 19. North America Homozygous Familial Hypercholesterolemia Treatment Sales YoY (2017-2028) & (K Pcs)
    Figure 20. North America Homozygous Familial Hypercholesterolemia Treatment Revenue YoY (2017-2028) & (US$ Million)
    Figure 21. Europe Homozygous Familial Hypercholesterolemia Treatment Sales YoY (2017-2028) & (K Pcs)
    Figure 22. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue YoY (2017-2028) & (US$ Million)
    Figure 23. Asia-Pacific Homozygous Familial Hypercholesterolemia Treatment Sales YoY (2017-2028) & (K Pcs)
    Figure 24. Asia-Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue YoY (2017-2028) & (US$ Million)
    Figure 25. Latin America Homozygous Familial Hypercholesterolemia Treatment Sales YoY (2017-2028) & (K Pcs)
    Figure 26. Latin America Homozygous Familial Hypercholesterolemia Treatment Revenue YoY (2017-2028) & (US$ Million)
    Figure 27. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Sales YoY (2017-2028) & (K Pcs)
    Figure 28. Middle East & Africa Homozygous Familial Hypercholesterolemia Treatment Revenue YoY (2017-2028) & (US$ Million)
    Figure 29. The Homozygous Familial Hypercholesterolemia Treatment Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 30. The Top 5 and 10 Largest Manufacturers of Homozygous Familial Hypercholesterolemia Treatment in the World: Market Share by Homozygous Familial Hypercholesterolemia Treatment Revenue in 2021
    Figure 31. Global Homozygous Familial Hypercholesterolemia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 32. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2017-2028)
    Figure 33. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2017-2028)
    Figure 34. Global Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2017-2028)
    Figure 35. Global Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2017-2028)
    Figure 36. North America Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2017-2028)
    Figure 37. North America Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2017-2028)
    Figure 38. North America Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2017-2028)
    Figure 39. North America Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2017-2028)
    Figure 40. North America Homozygous Familial Hypercholesterolemia Treatment Sales Share by Country (2017-2028)
    Figure 41. North America Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Country (2017-2028)
    Figure 42. U.S. Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 43. Canada Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 44. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2017-2028)
    Figure 45. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2017-2028)
    Figure 46. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2017-2028)
    Figure 47. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2017-2028)
    Figure 48. Europe Homozygous Familial Hypercholesterolemia Treatment Sales Share by Country (2017-2028)
    Figure 49. Europe Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Country (2017-2028)
    Figure 50. Germany Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 51. France Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 52. U.K. Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 53. Italy Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 54. Russia Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 55. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2017-2028)
    Figure 56. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2017-2028)
    Figure 57. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2017-2028)
    Figure 58. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2017-2028)
    Figure 59. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Sales Share by Region (2017-2028)
    Figure 60. Asia Pacific Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Region (2017-2028)
    Figure 61. China Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 62. Japan Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 63. South Korea Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 64. India Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 65. Australia Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 66. Taiwan Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 67. Indonesia Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 68. Thailand Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 69. Malaysia Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 70. Philippines Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 71. Latin America Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2017-2028)
    Figure 72. Latin America Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2017-2028)
    Figure 73. Latin America Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2017-2028)
    Figure 74. Latin America Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2017-2028)
    Figure 75. Latin America Homozygous Familial Hypercholesterolemia Treatment Sales Share by Country (2017-2028)
    Figure 76. Latin America Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Country (2017-2028)
    Figure 77. Mexico Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 78. Brazil Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 79. Argentina Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 80. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Type (2017-2028)
    Figure 81. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Type (2017-2028)
    Figure 82. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales Market Share by Application (2017-2028)
    Figure 83. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue Market Share by Application (2017-2028)
    Figure 84. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Sales Share by Country (2017-2028)
    Figure 85. Middle East and Africa Homozygous Familial Hypercholesterolemia Treatment Revenue Share by Country (2017-2028)
    Figure 86. Turkey Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 87. Saudi Arabia Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 88. UAE Homozygous Familial Hypercholesterolemia Treatment Revenue (2017-2028) & (US$ Million)
    Figure 89. Homozygous Familial Hypercholesterolemia Treatment Value Chain
    Figure 90. Homozygous Familial Hypercholesterolemia Treatment Production Process
    Figure 91. Channels of Distribution
    Figure 92. Distributors Profiles
    Figure 93. Bottom-up and Top-down Approaches for This Report
    Figure 94. Data Triangulation
    Figure 95. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
CymaBay Therapeutics Inc
Daewoong Co Ltd
Gemphire Therapeutics Inc
LipimetiX Development Inc
Regeneron Pharmaceuticals Inc
RegenxBio Inc
The Medicines Company
Frequently Asked Questions
Homozygous Familial Hypercholesterolemia Treatment report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Homozygous Familial Hypercholesterolemia Treatment report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Homozygous Familial Hypercholesterolemia Treatment report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports